Trials / Completed
CompletedNCT00291837
CT-2106 for the Second Line Treatment of Ovarian Cancer
Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- CTI BioPharma · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-2106 |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2006-06-01
- Completion
- 2007-12-01
- First posted
- 2006-02-15
- Last updated
- 2010-02-26
Locations
7 sites across 3 countries: France, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT00291837. Inclusion in this directory is not an endorsement.